Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System

Medical Therapy Solutions

Overview

Flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (WEB) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. The WEB was designed to treat wide-neck bifurcation aneurysms. This observational study will collect data about the routine practice in one center of using the WEB in ruptured and unruptured intracranial aneurysms. The primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.

Study Type

OBSERVATIONAL

Conditions

Ruptured and Unruptured Intracranial Aneurysms

Interventions

WEB aneurysm embolization systemDEVICE

The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient is at least 18 years old. 2. Patient is capable to undergo general anaesthesia. 3. Patient must sign and date the informed consent form prior to data registration. If patient is not able to give informed consent for himself/herself, a legally authorized representative must give informed consent on his/her behalf. 4. Patient has a ruptured or unruptured intracranial aneurysm requiring endovascular treatment. 5. Aneurysm with dome-to-neck ratio ≥ 1. 6. Aneurysm size favourable for WEB implantation (aneurysm width \< 10 mm or aneurysm width \> 3mm). Exclusion Criteria: 1. Patient is pregnant. 2. Patient has renal insufficiency (GRF \< 45 ml/min/1.73 m2). 3. Patient is unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history).

Locations (1)

University Hospital Antwerp

Edegem, Antwerp, Belgium

Outcomes

Primary Outcomes

Determination of anatomic outcome

grade of occlusion of the aneurysm assessed by MRA WEB Occlusion Scale: WOS A: complete occlusion WOS B: complete occlusion with opacification of the proximal recess WOS C: residual neck filling WOS D: residual aneurysm filling

Time frame: at 6 months

Determination of anatomic outcome

Time frame: at 24 months

Secondary Outcomes

Determination of procedural complications (Adverse events) during the operation

Procedural complications: aneurysm rupture, dissection, thromboembolic events (symptomatic and non-symptomatic), device protrusion through the neck of the aneurysm inside the parent artery, detachment problem, device stuck in microcatheter, bleeding.

Time frame: during index-procedure

Recording the use of additional devices during treatment.

Possible additional devices are stent, coils, flow diverter

Time frame: during index-procedure

Determination of the occurrence of post-procedural symptomatic thromboembolic events

Time frame: up to 24 months follow-up

Determination of clinical outcome: assessing disability of the patient by the modified Rankin Scale (mRS)

0 - No symptoms. 1. \- No significant disability. Able to carry out all usual activities, despite some symptoms. 2. \- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. \- Moderate disability. Requires some help, but able to walk unassisted. 4. \- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. \- Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. \- Dead.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: At baseline

Determination of clinical outcome: assessing disability of the patient by the modified Rankin Scale (mRS)

Time frame: at 6 to 8 weeks follow-up

Determination of clinical outcome: assessing disability of the patient by the modified Rankin Scale (mRS)

Time frame: at 6 months follow-up

Determination of clinical outcome: assessing disability of the patient by the modified Rankin Scale (mRS)

Time frame: at 24 months follow-up

Fisher grade (severity of intracranial SAH) for ruptured aneurysms.

Fisher grade: 1 No haemorrhage evident. 2 Subarachnoid haemorrhage less than 1mm thick. 3 Subarachnoid haemorrhage more than 1mm thick. 4 Subarachnoid haemorrhage of any thickness with intraventricular haemorrhage (IVH) or parenchymal extension.

Time frame: at baseline

Determination of technical success of the device

Technical success is defined as device deployment in the target aneurysm as intended by the investigator with adequate occlusion of the aneurysm (WOS A, B or C).

Time frame: during index-procedure

Determination of overall mortality

Time frame: up to 24 months

Recording of intracranial haemorrhage during follow-up

Time frame: up to 24 months

Recording the need for re-intervention during follow-up.

Time frame: up to 24 months

Hunt and Hess scale (severity of clinical effect of SAH) for ruptured aneurysms.

Hunt and Hess scale: 1. asymptomatic or minimal headache and slight neck stiffness, 70% survival 2. moderate to severe headache; neck stiffness; no neurologic deficit except cranial nerve palsy; 60% survival 3. drowsy; minimal neurologic deficit; 50% survival 4. stuporous; moderate to severe hemiparesis; possibly early decerebrate rigidity and vegetative disturbances; 20% survival 5. deep coma; decerebrate rigidity; moribund;10% survival

Time frame: baseline